血管浮腫治療薬市場：薬剤タイプ、投与経路、エンドユーザー別-2025-2030年の世界予測

血管浮腫治療薬市場は、2023年に46億9,000万米ドルと評価され、2024年には55億米ドルに達すると予測され、CAGR 17.28％で成長し、2030年には143億2,000万米ドルに達すると予測されています。

血管浮腫治療薬市場には、皮膚の下の突然の腫れを特徴とする血管浮腫の症状を管理・緩和するために設計された、幅広い治療薬や医薬品が含まれます。効果的な血管浮腫治療の必要性は、その潜在的な重症度や患者のQOLへの影響により高まっており、多くの場合、遺伝性および後天性のタイプに対する正確な治療が必要です。最終用途は病院、診療所、在宅医療など多岐にわたり、治療には急性発作の緊急管理や長期的な予防治療が含まれます。市場成長の原動力は、血管性浮腫に対する認識と診断の高まり、新規治療オプションにつながるバイオテクノロジーの進歩、ヘルスケアインフラへの投資の増加です。最新のビジネスチャンスは、標的生物学的製剤の開発と個別化医療アプローチに存在し、バイオテクノロジー企業が最前線に立ち、ゲノミクスと患者固有のデータを活用しています。メーカーは、診断率が上昇している新興国に焦点を当てることで、市場への浸透を高めることができます。しかし、生物学的製剤による治療には高いコスト、副作用の可能性、新しい治療法の承認を遅らせる規制上の課題などの制約があります。さらに、一部のヘルスケア提供者の知識格差は、過小診断や誤診につながり、市場成長に悪影響を及ぼす可能性があります。このような課題を克服するためには、費用対効果の高いバイオシミラーを開発し、正確な治療計画を立てるための遺伝子検査へのアクセスを強化することが必要です。血管性浮腫の分子経路の解明に重点を置いた調査により、画期的な治療法が生まれる可能性があります。同市場は、複数の既存プレーヤーとニッチセグメントに注力する新興企業によるダイナミックな競合が特徴であるため、絶え間ないイノベーションと戦略的提携が必要となります。企業が成長するためには、個別化治療のための研究開発に投資し、患者教育プログラムを拡大し、規制当局と積極的に関与して承認プロセスを合理化し、新規治療への迅速なアクセスを確保する必要があります。

市場力学：急速に進化する血管浮腫治療薬市場の主要市場インサイトを公開

血管浮腫治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 遺伝性血管性浮腫（HAE）の症例増加
  • 国民の意識レベル向上のためのイニシアチブの高まり
  • 疾患に関連する遺伝子変異の発生率の増加
• 市場抑制要因
  • 血管性浮腫の誤診
• 市場機会
  • 迅速な診断と最適な治療基準を提供するための政府の取り組み
  • 遺伝性血管性浮腫治療のための先進治療薬の開発
• 市場の課題
  • 治療に使用される薬剤の高コスト

ポーターの5つの力：血管浮腫治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血管浮腫治療薬市場における外部からの影響の把握

外部マクロ環境要因は、血管浮腫治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血管浮腫治療薬市場における競合情勢の把握

血管浮腫治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血管浮腫治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血管浮腫治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血管浮腫治療薬市場における成功への道筋を描く

血管浮腫治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性血管性浮腫（HAE）の症例増加
    • 国民の意識向上に向けた取り組みが拡大
    • 疾患関連遺伝子変異の発生率上昇
  • 抑制要因
    • 血管性浮腫の誤診
  • 機会
    • より迅速な診断を促進し、最適な治療基準を提供するための政府の取り組み
    • 遺伝性血管性浮腫疾患治療のための先進的治療法の開発
  • 課題
    • 治療に使用される薬剤の高コスト
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血管浮腫治療薬市場薬の種類別

• C1エステラーゼ阻害剤
  • ベリナート
  • シンライズ
  • ヘーガルダ
  • ルコネスト
• カリクレイン阻害剤
  • カルビトール
• 選択的ブラジキニンB2受容体拮抗薬
  • フィラジル

第7章 血管浮腫治療薬市場：投与経路別

• 注射
• オーラル

第8章 血管浮腫治療薬市場：エンドユーザー別

• クリニック
• 病院
• 調査機関

第9章 南北アメリカの血管浮腫治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の血管浮腫治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの血管浮腫治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adverum Biotechnologies, Inc.
• AMBOSS GmbH
• Apotex Corp.
• Attune Pharmaceuticals, Inc.
• BioCryst Pharmaceuticals, Inc.
• Cipla USA Inc.
• CSL Behring GmbH
• Fresenius Kabi USA, LLC
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals, Inc.
• Lecturio GmbH
• Merck & Co., Inc.
• Pharming Group N.V.
• Sanofi-Aventis Groupe S.A.
• Slayback Pharma LLC
• Takeda Pharmaceutical Company Limited
• Viropharma Biologics LLC

LIST OF FIGURES

• FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BERINERT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY CINRYZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HAEGARDA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RUCONEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY FIRAZYR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 79. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 80. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 81. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 82. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 86. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 87. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 88. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 115. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 127. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 133. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 139. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 151. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 152. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 158. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 164. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 170. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 176. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 182. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 188. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 189. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 190. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 191. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 194. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 200. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 206. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 212. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 213. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 214. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 215. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 218. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 219. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 220. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 221. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 224. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 230. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 242. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 247. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 248. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 253. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 259. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 260. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 265. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 266. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 271. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 272. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 278. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Angioedema Treatment Market was valued at USD 4.69 billion in 2023, expected to reach USD 5.50 billion in 2024, and is projected to grow at a CAGR of 17.28%, to USD 14.32 billion by 2030.

The market for angioedema treatment encompasses a wide array of therapies and medications designed to manage and alleviate the symptoms of angioedema, a condition characterized by sudden swelling beneath the skin. The necessity for effective angioedema treatments has grown due to its potential severity and impact on patients' quality of life, often necessitating precise treatments for hereditary and acquired types. Applications include emergency management of acute attacks and long-term preventive treatments, with end-use spanning hospitals, clinics, and home care settings. Market growth is driven by the rising awareness and diagnosis of angioedema, advancements in biotechnology leading to novel treatment options, and increased investment in healthcare infrastructure. Latest opportunities exist in the development of targeted biologics and personalized medicine approaches, with biotech firms at the forefront, leveraging genomics and patient-specific data. Manufacturers could enhance market penetration by focusing on emerging economies where diagnosis rates are increasing. However, limitations include high costs of biologic therapies, potential side effects, and regulatory challenges that can slow the approval of new treatments. Moreover, knowledge gaps among some healthcare providers can lead to underdiagnosis or misdiagnosis, impacting market growth negatively. To overcome these challenges, innovation can be geared towards cost-effective biosimilars and enhancing genetic testing access for precise treatment plans. Research focused on uncovering molecular pathways of angioedema may yield breakthrough therapies. The market is characterized by dynamic competition with several established players and emerging startups focusing on niche segments, thus requiring constant innovation and strategic partnerships. For growth, businesses should invest in R&D for personalized treatments, expand patient education programs, and actively engage with regulatory bodies to streamline the approval processes, thereby ensuring faster access to novel therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angioedema Treatment Market

The Angioedema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of hereditary angioedema (HAE)
  • Growing initiatives for improving awareness levels among the population
  • Rising incidence of disease-related genetic mutations
• Market Restraints
  • Misdiagnosis of angioedema
• Market Opportunities
  • Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
  • Development of advance therapeutics for hereditary angioedema disorders treatment
• Market Challenges
  • High cost of the drugs used for treatment

Porter's Five Forces: A Strategic Tool for Navigating the Angioedema Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angioedema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angioedema Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angioedema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angioedema Treatment Market

A detailed market share analysis in the Angioedema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angioedema Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angioedema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angioedema Treatment Market

A strategic analysis of the Angioedema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drugs Type, market is studied across C1 Esterase Inhibitor, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist. The C1 Esterase Inhibitor is further studied across Berinert, Cinryze, Haegarda, and Ruconest. The Kallikrein Inhibitor is further studied across Kalbitor. The Selective Bradykinin B2 Receptor Antagonist is further studied across Firazyr.
• Based on Route of Administration, market is studied across Injections and Oral.
• Based on End-User, market is studied across Clinics, Hospitals, and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of hereditary angioedema (HAE)
    • 5.1.1.2. Growing initiatives for improving awareness levels among the population
    • 5.1.1.3. Rising incidence of disease-related genetic mutations
  • 5.1.2. Restraints
    • 5.1.2.1. Misdiagnosis of angioedema
  • 5.1.3. Opportunities
    • 5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
    • 5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of the drugs used for treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Angioedema Treatment Market, by Drugs Type

• 6.1. Introduction
• 6.2. C1 Esterase Inhibitor
  • 6.2.1. Berinert
  • 6.2.2. Cinryze
  • 6.2.3. Haegarda
  • 6.2.4. Ruconest
• 6.3. Kallikrein Inhibitor
  • 6.3.1. Kalbitor
• 6.4. Selective Bradykinin B2 Receptor Antagonist
  • 6.4.1. Firazyr

7. Angioedema Treatment Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injections
• 7.3. Oral

8. Angioedema Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Hospitals
• 8.4. Research Organizations

9. Americas Angioedema Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Angioedema Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Angioedema Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adverum Biotechnologies, Inc.
• 2. AMBOSS GmbH
• 3. Apotex Corp.
• 4. Attune Pharmaceuticals, Inc.
• 5. BioCryst Pharmaceuticals, Inc.
• 6. Cipla USA Inc.
• 7. CSL Behring GmbH
• 8. Fresenius Kabi USA, LLC
• 9. Ionis Pharmaceuticals, Inc.
• 10. KalVista Pharmaceuticals, Inc.
• 11. Lecturio GmbH
• 12. Merck & Co., Inc.
• 13. Pharming Group N.V.
• 14. Sanofi-Aventis Groupe S.A.
• 15. Slayback Pharma LLC
• 16. Takeda Pharmaceutical Company Limited
• 17. Viropharma Biologics LLC